NRIXNasdaqPharmaceutical PreparationsFiscal year ends November 30
Nurix Therapeutics, Inc.
Financials through Q3 FY2026, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 13, 2026
$24.93+0.51 (+2.09%)
Close on Oct 19, 2026
- Market cap
- $2.90B
- P/E (TTM)
- 10.8
- Dividend yield
- 0.00%
Nurix Therapeutics, Inc. income statement
Ratios
Latest available, balances at Aug 31, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- 41.3%
- Net margin
- 42.0%
- Return on equity, FY2025
- -49.6%
Financial strength
- Current ratio
- 8.44
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 550.9%
Valuation
- P/E ratio
- 10.8
- Price to sales
- 4.13
- Price to book
- 2.99
- Dividend yield
- 0.00%